Market Overview

Investors In Avanir Cheer As Piper Jaffray Lifts Target On Stock Sharply From $6 To $13

Related AVNR
Avanir Pharmaceuticals Announces FDA Acceptance Of IND For AVP-786, Used For Adjunctive Treatment Of Major Depressive Disorder
AVANIR Pharma Offers Three Presentations for AVP-825 for Acute Treatment of Migraine

Shares of Avanir Pharma (NASDAQ: AVNR) have rallied more than 5 percent Monday afternoon following some bullish comments and a raise price target from Piper Jaffray's Charles Duncan earlier. Avanir shares had traded up as much as 13 percent in the pre-market session.

The analyst more than doubled his price target on the stock from $6 to $13, citing a clear distinction from Neudexta generics and Avanir's next-gen AVP-786. Duncan believes the company's franchise will expand into 2030 or beyond.

Piper Jaffray currently rates Avanir shares at an Overweight.

With the stock trading up to around $5.23 at last check, Duncan's new price target implies potential upside of nearly 150 percent.

Posted-In: Analyst Color News Price Target Analyst Ratings Movers


Related Articles (AVNR)

Around the Web, We're Loving...

Partner Network

Get Benzinga's Newsletters